Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
Business Insider20d
Sweetgreen options imply 15.7% move in share price post-earnings
Pre-earnings options volume in Sweetgreen (SG) is 6.5x normal with calls leading puts 10:9. Implied volatility suggests the market is anticipating a move near 15.7%, or $3.64, after results are ...
Healio8d
CagriSema confers 15.7% weight loss at 68 weeks for adults with obesity, type 2 diabetes
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Becker's Hospital Review8d
Novo Nordisk drug yields 15.7% weight loss in phase 3 trial
Discover the latest experimental obesity drug from Novo Nordisk, achieving 15.7% weight loss after 68 weeks, which fell short of the company's expectations.
Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
Business Insider1mon
Applovin options imply 15.7% move in share price post-earnings
Pre-earnings options volume in Applovin (APP) is 2.0x normal with calls leading puts 3:2. Implied volatility suggests the market is anticipating a move near 15.7%, or $60.11, after results are ...